Abstract: By finding a novel tetrahydrofolate synthetase gene and a protein encoded by said gene, a method for identifying a compound which inhibits cell growth accelerating activity of said protein is provided, and a judging method, a preventing method and a treating method of colon cancer are provided. A DNA comprising a nucleotide sequence of from the 94th to 2934th positions of the nucleotide sequence of SEQ ID NO:1 of the SEQUENCE LISTING; a polynucleotide which specifically hybridizes with said DNA; a protein encoded by said DNA; a recombinant vector comprising said DNA; a transformant comprising said recombinant vector; an antibody for said protein; a method for producing said protein; a method for identifying a compound which inhibits cell growth accelerating activity possessed by said protein; a method for judging colon cancer, characterizing in that expressed amount of said DNA is measured; a kit for judging colon cancer; a preventive agent and/or therapeutic agent for colon cancer.

Abstract: Ligand Drug Conjugates are provided having a DR5 binding moiety attached via linking groups and/or spacers to a therapeutic agent and are effective in treatment of various cancers.

Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Abstract: The present invention provides methods of preventing and/or treating multiple organ failure comprising the step of administering a therapeutically effective amount of agent comprising tumor cytotoxic factor-II (TCF-II) or hepatocyte growth factor (HGF). Methods of the present invention will be useful for preventing and/or treating the development of multiple organ failure resulting from burn, disseminated intravascular coagulation (DIC), circulatory failure, hemorrhagic shock, infectious disease, acute pancreatitis, ischemic disorder, hepatorenal syndrome, gastrointestinal hemorrhage, nutritional metabolic failure, terminal cancer, acquired immunodeficiency syndrome (AIDS), deterioration of systemic conditions due to radiation affection, and cachexia.